摘要
克罗恩病(Crohn's disease,CD)是一种累及全消化道的跳跃性全层炎症性肠病,肛瘘是CD常见的临床表现之一,临床发病率可达28％～43％.CD肛瘘的治疗需要结合患者的实际情况选择个体化的治疗方案,包括合适的药物种类和手术方法,目前并没有高成功率的金标准治疗方案,临床复发率较高.间充质干细胞(mesenchymal stem cell,MSC)是一种多能干细胞,具有自我更新和分化为多种类型细胞的能力,被广泛应用于再生医学领域,MSC疗法对于CD患者是一种富有前景的新选择.与传统治疗手段相比,MSC在诱导和维持瘘管闭合方面表现出更高的效率,具有很强的免疫调节作用和微创性,特别是对于瘘管复杂、常规治疗不耐受的患者.本文结合国内外最新研究报道,就MSC治疗CD肛瘘的研究进展进行综述.
Abstract
Crohn's disease(CD)is a leaping full-layer inflammatory bowel disease involving the whole diges-tive tract.Anal fistula is one of the common clinical manifestations CD,with a clinical incidence of 28％-43％.The treatment of CD anal fistula needs to be combined with the actual situation of the patient to select an individu-alized treatment plan,including appropriate drug types and surgical methods.Currently,there is no gold standard treatment plan with a high success rate,and the clinical recurrence rate is high.Mesenchymal stem cells(MSC)are pluripotent stem cells that have the ability to self-renew and differentiate into multiple cell types and are widely used in the field of regenerative medicine.MSC therapy is a promising new treatment option for patients with CD.Compared with traditional treatments,MSC showed higher efficiency in inducing and maintaining fistula closure,and had a strong immunomodulatory effect and was minimally invasive.Especially for patients with complex fistu-las that are intolerant to conventional treatment.Based on the latest research reports at home and abroad,this ar-ticle reviews the research progress of MSC in treating anal fistula in CD.
维普
万方数据